Related Experiment Videos
Drug therapy of severe hypercholesterolemia in patients with coronary artery disease
K G Parhofer1, W O Richter, P Schwandt
1Medical Department II, Klinikum Grosshadern, Ludwig-Maximilians University, Munich, Germany.
Insights
Cholesterol-lowering therapy is crucial for secondary prevention in coronary artery disease (CAD) patients, aiming for low-density lipoprotein (LDL) below 100 mg/dl. This treatment reduces lesion progression, activation, and improves blood vessel function.
Area of Science:
- Cardiology
- Pharmacology
- Preventive Medicine
Background:
- Coronary artery disease (CAD) management emphasizes secondary prevention.
- Cholesterol-lowering therapy significantly benefits patients with established CAD.
- Therapeutic targets include reducing low-density lipoprotein (LDL) cholesterol levels.
Purpose of the Study:
- To outline the benefits of cholesterol-lowering therapy in secondary CAD prevention.
- To detail therapeutic goals for LDL cholesterol levels.
- To review pharmacological approaches for hyperlipoproteinemia in CAD patients.
Main Methods:
- Review of established cholesterol-lowering treatment strategies.
- Classification of hyperlipoproteinemia types (isolated LDL vs. combined hyperlipidemia).
- Description of single-drug and combination therapy options.
Main Results:
- Cholesterol-lowering therapy reduces lesion progression and activation.
- Improved endothelial vasomotor function is a key benefit.
- Specific drug classes (bile acid resins, HMG-CoA reductase inhibitors, nicotinic acid, fibric acids) are recommended based on lipid profiles.
Conclusions:
- Achieving target LDL cholesterol levels is vital for CAD secondary prevention.
- Pharmacological interventions are tailored to specific hyperlipoproteinemia types.
- Effective management involves strategic single-drug or combination therapies.
Abstract:
The beneficial effect of cholesterol-lowering therapy for secondary prevention in patients with coronary artery disease (CAD) is well established. The therapeutic goal in this situation is a low-density lipoprotein (LDL) cholesterol level of 100 mg/dl. Cholesterol-lowering therapy will not only lead to a reduction in the progression of lesions but also and probably more importantly will reduce lesion activation and rupture and improve endothelial vasomotor function. Depending on the underlying hyperlipoproteinemia, the first choice for single drug therapy is a bile acid-binding resin or a hepatic hydroxymethyl glutaryl coenzyme A (HMG-CoA) reductase inhibitor in isolated LDL hypercholesterolemia, and nicotinic acid, a fibric acid, or a HMG-CoA reductase inhibitor in combined hyperlipidemia. Combination therapy usually consists of a bile acid-binding resin with either an HMG-CoA reductase inhibitor, a fibric acid, or nicotinic acid in LDL hypercholesterolemia and nicotinic acid with a fibric acid in combined hyperlipidemia.